HARMONY BIOSCIENCES HOLDINGS (HRMY) Fundamental Analysis & Valuation

NASDAQ:HRMY • US4131971040

Current stock price

27.86 USD
+0.12 (+0.43%)
Last:

This HRMY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. HRMY Profitability Analysis

1.1 Basic Checks

  • In the past year HRMY was profitable.
  • In the past year HRMY had a positive cash flow from operations.
  • In the past 5 years HRMY has always been profitable.
  • In the past 5 years HRMY always reported a positive cash flow from operatings.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 12.48%, HRMY belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 18.24%, HRMY belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
  • The Return On Invested Capital of HRMY (15.30%) is better than 94.27% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for HRMY is significantly above the industry average of 13.06%.
Industry RankSector Rank
ROA 12.48%
ROE 18.24%
ROIC 15.3%
ROA(3y)14.31%
ROA(5y)15.57%
ROE(3y)22.63%
ROE(5y)26.3%
ROIC(3y)18.27%
ROIC(5y)17.43%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K

1.3 Margins

  • With an excellent Profit Margin value of 18.27%, HRMY belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
  • In the last couple of years the Profit Margin of HRMY has declined.
  • HRMY has a better Operating Margin (24.00%) than 91.15% of its industry peers.
  • In the last couple of years the Operating Margin of HRMY has grown nicely.
  • HRMY has a better Gross Margin (77.16%) than 83.33% of its industry peers.
  • HRMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24%
PM (TTM) 18.27%
GM 77.16%
OM growth 3Y-4.37%
OM growth 5Y17.8%
PM growth 3Y-23.89%
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y-1.37%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. HRMY Health Analysis

2.1 Basic Checks

  • HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for HRMY has been increased compared to 1 year ago.
  • HRMY has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, HRMY has an improved debt to assets ratio.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • HRMY has an Altman-Z score of 4.42. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
  • HRMY has a Altman-Z score of 4.42. This is in the better half of the industry: HRMY outperforms 73.96% of its industry peers.
  • The Debt to FCF ratio of HRMY is 0.50, which is an excellent value as it means it would take HRMY, only 0.50 years of fcf income to pay off all of its debts.
  • HRMY has a better Debt to FCF ratio (0.50) than 96.35% of its industry peers.
  • A Debt/Equity ratio of 0.17 indicates that HRMY is not too dependend on debt financing.
  • HRMY has a Debt to Equity ratio (0.17) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 0.5
Altman-Z 4.42
ROIC/WACC1.64
WACC9.35%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 3.60 indicates that HRMY has no problem at all paying its short term obligations.
  • The Current ratio of HRMY (3.60) is comparable to the rest of the industry.
  • A Quick Ratio of 3.58 indicates that HRMY has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.58, HRMY is in line with its industry, outperforming 58.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.58
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HRMY Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.97% over the past year.
  • Measured over the past years, HRMY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.69% on average per year.
  • The Revenue has grown by 21.51% in the past year. This is a very strong growth!
  • Measured over the past years, HRMY shows a very strong growth in Revenue. The Revenue has been growing by 40.31% on average per year.
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
Revenue 1Y (TTM)21.51%
Revenue growth 3Y25.64%
Revenue growth 5Y40.31%
Sales Q2Q%21.12%

3.2 Future

  • Based on estimates for the next years, HRMY will show a small growth in Earnings Per Share. The EPS will grow by 6.39% on average per year.
  • The Revenue is expected to grow by 5.39% on average over the next years.
EPS Next Y33.68%
EPS Next 2Y26.09%
EPS Next 3Y23.17%
EPS Next 5Y6.39%
Revenue Next Year17.86%
Revenue Next 2Y15.35%
Revenue Next 3Y14.14%
Revenue Next 5Y5.39%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

9

4. HRMY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 10.28, which indicates a very decent valuation of HRMY.
  • 90.63% of the companies in the same industry are more expensive than HRMY, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.17. HRMY is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 7.69 indicates a rather cheap valuation of HRMY.
  • Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 91.15% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 23.05. HRMY is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.28
Fwd PE 7.69
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 97.40% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, HRMY is valued cheaply inside the industry as 96.35% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.9
EV/EBITDA 4.15
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HRMY may justify a higher PE ratio.
  • A more expensive valuation may be justified as HRMY's earnings are expected to grow with 23.17% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y26.09%
EPS Next 3Y23.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HRMY Dividend Analysis

5.1 Amount

  • HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HRMY Fundamentals: All Metrics, Ratios and Statistics

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (4/6/2026, 12:36:22 PM)

27.86

+0.12 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners89.56%
Inst Owner Change0%
Ins Owners1.62%
Ins Owner Change-0.23%
Market Cap1.61B
Revenue(TTM)868.45M
Net Income(TTM)158.69M
Analysts75.29
Price Target42.84 (53.77%)
Short Float %15.17%
Short Ratio8.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.41%
Min EPS beat(2)-58.44%
Max EPS beat(2)1.62%
EPS beat(4)2
Avg EPS beat(4)-9.25%
Min EPS beat(4)-58.44%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)51.32%
EPS beat(12)8
Avg EPS beat(12)36.66%
EPS beat(16)11
Avg EPS beat(16)92.62%
Revenue beat(2)1
Avg Revenue beat(2)2.19%
Min Revenue beat(2)-0.58%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.02%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-0.78%
Revenue beat(12)3
Avg Revenue beat(12)-0.81%
Revenue beat(16)5
Avg Revenue beat(16)-0.7%
PT rev (1m)-7.97%
PT rev (3m)-9.06%
EPS NQ rev (1m)-0.81%
EPS NQ rev (3m)-12.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.26%
Revenue NQ rev (1m)-0.87%
Revenue NQ rev (3m)1.82%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)1.76%
Valuation
Industry RankSector Rank
PE 10.28
Fwd PE 7.69
P/S 1.86
P/FCF 4.9
P/OCF 4.63
P/B 1.85
P/tB 2.06
EV/EBITDA 4.15
EPS(TTM)2.71
EY9.73%
EPS(NY)3.62
Fwd EY13%
FCF(TTM)5.68
FCFY20.39%
OCF(TTM)6.02
OCFY21.61%
SpS15.01
BVpS15.05
TBVpS13.5
PEG (NY)0.31
PEG (5Y)N/A
Graham Number30.29
Profitability
Industry RankSector Rank
ROA 12.48%
ROE 18.24%
ROCE 20.45%
ROIC 15.3%
ROICexc 63.88%
ROICexgc 100.8%
OM 24%
PM (TTM) 18.27%
GM 77.16%
FCFM 37.84%
ROA(3y)14.31%
ROA(5y)15.57%
ROE(3y)22.63%
ROE(5y)26.3%
ROIC(3y)18.27%
ROIC(5y)17.43%
ROICexc(3y)50.91%
ROICexc(5y)46.17%
ROICexgc(3y)83.62%
ROICexgc(5y)1001.65%
ROCE(3y)24.42%
ROCE(5y)23.3%
ROICexgc growth 3Y7.52%
ROICexgc growth 5YN/A
ROICexc growth 3Y24.53%
ROICexc growth 5Y26.45%
OM growth 3Y-4.37%
OM growth 5Y17.8%
PM growth 3Y-23.89%
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y-1.37%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 0.5
Debt/EBITDA 0.61
Cap/Depr 77.21%
Cap/Sales 2.25%
Interest Coverage 14.2
Cash Conversion 148.93%
Profit Quality 207.1%
Current Ratio 3.6
Quick Ratio 3.58
Altman-Z 4.42
F-Score5
WACC9.35%
ROIC/WACC1.64
Cap/Depr(3y)27.76%
Cap/Depr(5y)157.72%
Cap/Sales(3y)0.82%
Cap/Sales(5y)8.9%
Profit Quality(3y)175.8%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
EPS Next Y33.68%
EPS Next 2Y26.09%
EPS Next 3Y23.17%
EPS Next 5Y6.39%
Revenue 1Y (TTM)21.51%
Revenue growth 3Y25.64%
Revenue growth 5Y40.31%
Sales Q2Q%21.12%
Revenue Next Year17.86%
Revenue Next 2Y15.35%
Revenue Next 3Y14.14%
Revenue Next 5Y5.39%
EBIT growth 1Y0.5%
EBIT growth 3Y20.15%
EBIT growth 5Y65.28%
EBIT Next Year34.86%
EBIT Next 3Y11.95%
EBIT Next 5Y7.8%
FCF growth 1Y50.29%
FCF growth 3Y46.6%
FCF growth 5YN/A
OCF growth 1Y58.4%
OCF growth 3Y34.07%
OCF growth 5YN/A

HARMONY BIOSCIENCES HOLDINGS / HRMY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?

ChartMill assigns a fundamental rating of 7 / 10 to HRMY.


What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.


What is the profitability of HRMY stock?

HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.


What is the financial health of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

The financial health rating of HARMONY BIOSCIENCES HOLDINGS (HRMY) is 7 / 10.